IMPORTANT SAFETY INFORMATION: Myrbetriq is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet.

Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg).

Please see additional Important Safety Information below.

Think beta‑3. Think MYRBETRIQ® (mirabegron). The first and only FDA-approved overactive bladder (OAB) treatment in its class.

MYRBETRIQ® (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

It is not an antimuscarinic agent.1

By targeting the beta‑3 adrenergic receptor (AR) pathway, MYRBETRIQ® (mirabegron) impacts the storage phase of the micturition cycle1

The bladder performs 2 major functions2:

  • Relaxation of the detrusor muscle to store urine
  • Contraction of the detrusor muscle to void urine

See how MYRBETRIQ targets the beta‑3 AR pathway

  • OAB is characterized by involuntary contraction of the detrusor muscle during the storage phase3
  • Mirabegron, an agonist of the human beta‑3 AR, relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activating the beta‑3 AR pathway, increasing bladder capacity1
  • Although mirabegron showed very low intrinsic activity for cloned human beta‑1 AR and beta‑2 AR, results in humans indicate that beta‑1 AR stimulation occurred at a mirabegron dose of 200 mg1

Mechanism of Action: Step by Step